Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Imprint Wealth LLC

Imprint Wealth LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 6,623.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 198,757 shares of the biopharmaceutical company’s stock after purchasing an additional 195,801 shares during the period. Bristol-Myers Squibb accounts for approximately 0.8% of Imprint Wealth LLC’s portfolio, making the stock its 4th largest position. Imprint Wealth LLC’s holdings in Bristol-Myers Squibb were worth $19,876,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Bank Julius Baer & Co. Ltd Zurich increased its stake in Bristol-Myers Squibb by 86,002.1% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 659,143,253 shares of the biopharmaceutical company’s stock valued at $42,152,211,000 after purchasing an additional 658,377,716 shares during the period. Norges Bank acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $1,873,696,000. Moneta Group Investment Advisors LLC raised its stake in Bristol-Myers Squibb by 114,228.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock valued at $1,544,751,000 after acquiring an additional 21,451,006 shares during the last quarter. Capital International Investors grew its stake in shares of Bristol-Myers Squibb by 12.8% in the 2nd quarter. Capital International Investors now owns 69,296,006 shares of the biopharmaceutical company’s stock valued at $4,431,517,000 after purchasing an additional 7,878,833 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Bristol-Myers Squibb by 193.4% in the first quarter. Envestnet Asset Management Inc. now owns 7,214,000 shares of the biopharmaceutical company’s stock valued at $186,351,000 after purchasing an additional 4,755,058 shares during the period. Hedge funds and other institutional investors own 74.98% of the company’s stock.

Bristol-Myers Squibb Trading Down 4.2 %

Shares of NYSE BMY traded down $2.15 during midday trading on Monday, reaching $48.69. 15,746,585 shares of the stock were exchanged, compared to its average volume of 9,684,396. The company has a current ratio of 1.18, a quick ratio of 1.07 and a debt-to-equity ratio of 1.11. The company has a market capitalization of $99.07 billion, a P/E ratio of 12.63, a P/E/G ratio of 1.62 and a beta of 0.38. The stock has a 50 day moving average price of $55.60 and a 200-day moving average price of $60.85. Bristol-Myers Squibb has a 52-week low of $48.42 and a 52-week high of $81.43.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.76 by $0.24. Bristol-Myers Squibb had a return on equity of 51.59% and a net margin of 18.44%. The business had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $10.96 billion. During the same quarter last year, the firm earned $1.99 earnings per share. The business’s revenue was down 2.2% on a year-over-year basis. Equities research analysts expect that Bristol-Myers Squibb will post 7.56 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $2.28 dividend on an annualized basis and a yield of 4.68%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 57.87%.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Ann Powell sold 17,986 shares of Bristol-Myers Squibb stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the sale, the executive vice president now owns 27,868 shares in the company, valued at $1,706,915. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.09% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on BMY. Atlantic Securities lowered their price objective on shares of Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, July 28th. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Friday, October 27th. TD Cowen reduced their price objective on shares of Bristol-Myers Squibb from $80.00 to $66.00 and set a “market perform” rating for the company in a research report on Friday, September 15th. The Goldman Sachs Group dropped their target price on Bristol-Myers Squibb from $81.00 to $69.00 and set a “buy” rating on the stock in a research report on Monday, October 30th. Finally, Bank of America reduced their price target on Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating for the company in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $63.59.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.